Chardan analyst Keay Nakae raised the firm’s price target on Dyne Therapeutics to $20 from $17 and keeps a Buy rating on the shares post the Q4 results. The analyst believes the initial safety and efficacy data from the DYNE-101 and DYNE-251 programs will provide important clinical proof of concept for the Dyne’s Force platform to successfully deliver to ex-hepatic targets.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DYN:
- Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
- Dyne Therapeutics expects cash to fund operations through 2024
- Dyne Therapeutics reports Q4 EPS (74c), consensus (84c)
- Dyne Therapeutics upgraded to Strong Buy from Outperform at Raymond James
- Oppenheimer starts Dyne Therapeutics at Outperform with $34 price target
